SOX2 and head and neck squamous cell carcinoma: SOX2 was identified as a direct target of TAZ for the modulation of CSCs self-renewal and maintenance in HNSCC implicating that targeting the TAT/TAZ/TEAD4-SOX2 axis might count as an amenable target for HNSCC therapy (Li J. et al., 2019).